147 related articles for article (PubMed ID: 10428933)
21. Clinical pharmacokinetics of quinupristin/dalfopristin.
Bearden DT
Clin Pharmacokinet; 2004; 43(4):239-52. PubMed ID: 15005638
[TBL] [Abstract][Full Text] [Related]
22. Subinhibitory quinupristin/dalfopristin attenuates virulence of Staphylococcus aureus.
Koszczol C; Bernardo K; Krönke M; Krut O
J Antimicrob Chemother; 2006 Sep; 58(3):564-74. PubMed ID: 16895938
[TBL] [Abstract][Full Text] [Related]
23. Two 2-hydroxy-3-alkyl-1,4-naphthoquinones with in vitro and in vivo activities against Toxoplasma gondii.
Khan AA; Nasr M; Araujo FG
Antimicrob Agents Chemother; 1998 Sep; 42(9):2284-9. PubMed ID: 9736550
[TBL] [Abstract][Full Text] [Related]
24. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.
Nichols RL; Graham DR; Barriere SL; Rodgers A; Wilson SE; Zervos M; Dunn DL; Kreter B
J Antimicrob Chemother; 1999 Aug; 44(2):263-73. PubMed ID: 10473234
[TBL] [Abstract][Full Text] [Related]
25. [Comparative activity of several antibiotics against Toxoplasma gondii in a mouse model].
Rodríguez-Díaz JC; Martínez-Grueiro MM; Martínez-Fernández AR
Enferm Infecc Microbiol Clin; 1993 Dec; 11(10):543-6. PubMed ID: 8142504
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of quinupristin/dalfopristin (Synercid) and RPR 106972 stability in susceptibility testing media.
Marshall SA; Kugler KC; Jones RN
Int J Antimicrob Agents; 2000 Aug; 15(4):291-7. PubMed ID: 10929879
[TBL] [Abstract][Full Text] [Related]
27. Quinupristin/dalfopristin attenuates the inflammatory response and reduces the concentration of neuron-specific enolase in the cerebrospinal fluid of rabbits with experimental Streptococcus pneumoniae meningitis.
Trostdorf F; Reinert RR; Schmidt H; Nichterlein T; Stuertz K; Schmitz-Salue M; Sadowski I; Brück W; Nau R
J Antimicrob Chemother; 1999 Jan; 43(1):87-94. PubMed ID: 10381105
[TBL] [Abstract][Full Text] [Related]
28. In-vitro activity of quinupristin/dalfopristin (Synercid) against isolates of Streptococcus pneumoniae, Staphylococcus aureus and enterococcus spp.
Johnson AP; Warner M; Speller DC
J Antimicrob Chemother; 1997 Oct; 40(4):604-5. PubMed ID: 9372437
[No Abstract] [Full Text] [Related]
29. In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates.
Qadri SM; Ueno Y; Abu Mostafa FM; Halim M
Chemotherapy; 1997; 43(2):94-9. PubMed ID: 9084917
[TBL] [Abstract][Full Text] [Related]
30. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
Kang SL; Rybak MJ
J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
[TBL] [Abstract][Full Text] [Related]
31. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
32. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis.
Fantin B; Leclercq R; Garry L; Carbon C
Antimicrob Agents Chemother; 1997 May; 41(5):931-5. PubMed ID: 9145847
[TBL] [Abstract][Full Text] [Related]
33. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium.
Hill RL; Smith CT; Seyed-Akhavani M; Casewell MW
J Antimicrob Chemother; 1997 May; 39 Suppl A():23-8. PubMed ID: 9511058
[TBL] [Abstract][Full Text] [Related]
34. Quinupristin/dalfopristin: a therapeutic review.
Allington DR; Rivey MP
Clin Ther; 2001 Jan; 23(1):24-44. PubMed ID: 11219478
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of quinupristin/dalfopristin (RP 59500) against a large collection of infrequently isolated or tested species.
Barrett MS; Jones RN
Diagn Microbiol Infect Dis; 1996 Jul; 25(3):147-9. PubMed ID: 8902412
[TBL] [Abstract][Full Text] [Related]
36. Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo.
Mui EJ; Jacobus D; Milhous WK; Schiehser G; Hsu H; Roberts CW; Kirisits MJ; McLeod R
Antimicrob Agents Chemother; 2005 Aug; 49(8):3463-7. PubMed ID: 16048961
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.
Wang FD; Lin ML; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):433-9. PubMed ID: 10925532
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
[TBL] [Abstract][Full Text] [Related]
39. Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondii.
Khan AA; Slifer TR; Araujo FG; Remington JS
Antimicrob Agents Chemother; 2001 Jan; 45(1):48-51. PubMed ID: 11120943
[TBL] [Abstract][Full Text] [Related]
40. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
